This article (page 22) discusses the need of different models for clinical studies and features prominently the Transparency Life Sciences model.http://digital.lifescienceleadermag.com/link/lslead/2011/jul/1?s=0
“The obvious place to start is finding new clinical indications and
uses for generic drugs. We already know a lot about their modes of
actions and their safety profiles, and repurposing them for other indi-
cations has a higher probability of success than developing new or
novel drugs.”
Tomasz Sablinski, M.D., Ph.D., managing director at Celtic Therapeutics
No comments:
Post a Comment